The pathway-selective estrogen receptor ligand WAY-169916 reduces infarct size after myocardial ischemia and reperfusion by an estrogen receptor dependent mechanism

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 6, 2007, Pages 401-407

  Booth, Erin A ^a   Marchesi, Marta ^a   Knittel, Andrea K ^a   Kilbourne, Edward J ^b   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

Estrogen; Heart; ICI 182,780; Ischemia; Neutrophil

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; UNCLASSIFIED DRUG; WAY 169916;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALS; DISEASE MODELS, ANIMAL; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; LIGANDS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OVARIECTOMY; PYRAZOLES; RABBITS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 34347252662     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180544527     Document Type: Article

References (40)

1. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999;20:358-417.
2. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol. 2001;63:165-92.
3. Toran-Allerand CD. Minireview: A plethora of estrogen receptors in the brain: where will it end? Endocrinology. 2004;145:1069-1074.
4. Henderson BE, Ross RK, Paganini-Hill A, et al. Estrogen use and cardiovascular disease. Am J Obstet Gynecol. 1986;154:1181-1186.
5. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology. 1994;135:2001-2005.
6. Fillet HWH, Cholsst I, Luine V, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimers type. Psychoneuroendocrinology, 1986;11:337-345.
7. Tsai CH, Su SF, Chou TF, et al. Differential effects of sarcolemmal and mitochondrial K(ATP) channels activated by 17 beta-estradiol on reperfusion arrhythmias and infarct sizes in canine hearts. J Pharmacol Exp Ther. 2002;301:234-240.
8. Hale SL, Birnbaum Y, Kloner RA. beta-Estradiol, but not alpha-estradiol, reduced myocardial necrosis in rabbits after ischemia and reperfusion. Am Heart J. 1996;132:258-262.
9. Booth EA, Marchesi M, Kilbourne EJ, et al. 17Beta-estradiol as a receptor-mediated cardioprotective agent. J Pharmacol Exp Ther. 2003;307:395-401.
10. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation. 2000;102:2687-2693.
11. Telci A, Cakatay U, Akhan SE, et al. Postmenopausal hormone replacement therapy use decreases oxidative protein damage. Gynecol Obstet Invest. 2002;54:88-93.
12. Kuhl H. Beyond hormonal action: are oestrogens effective free radical scavengers? Maturitas. 1993;18:5-8.
13. Sack MN, Rader DJ, Cannon RO 3rd. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269-270.
14. Pelzer T, Neumann M, de Jager T, et al. Estrogen effects in the myocardium: inhibition of NF-kappaB DNA binding by estrogen receptor-alpha and -beta. Biochem Biophys Res Commun. 2001;286:1153-1157.
15. Chadwick CC, Chippari S, Matelan E, et al. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc Natl Acad Sci U S A. 2005;102:2543-2548.
16. Kilgore KS, Park JL, Chi L, et al. Reduction of myocardial infarct size in the rabbit by a carbohydrate analog of sialyl lewis(x). J Cardiovasc Pharmacol Ther. 1996;1:49-56.
17. Steffan RJ, Matelan E, Ashwell MA, et al. Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. J Med Chem. 2004;47:6435-6438.
18. Harnish DC, Liu X, Kenney T, et al. The pathway-selective estrogen receptor ligand WAY-169916 displays differential activity in ischemia-reperfusion injury models. J Cardiovasc Pharmacol. 2006;47:788-795.
19. Howell A, Osborne CK, Morris C, et al. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000;89:817-825.
20. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2-S6.
21. Keith JC Jr, Albert LM, Leathurby Y, et al. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappaB transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R427-R438.
22. Ogita H, Node K, Asanuma H, et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Am Coll Cardiol. 2002;40:998-1005.
23. Ogita H, Node K, Liao Y, et al. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension. 2004;43:237-242.
24. Sbarouni E, Iliodromitis EK, Bofilis E, et al. Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J Pharmacol. 2003;467:163-168.
25. Kilgore KS, Park JL, Tanhehco EJ, et al. Attenuation of interleukin-8 expression in C6-deficient rabbits after myocardial ischemia/reperfusion. J Mol Cell Cardiol. 1998;30:75-85.
26. Schafer H, Mathey D, Hugo F, et al. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol. 1986;137:1945-1949.
27. Tanhehco EJ, Kilgore KS, Liff DA, et al. The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system. Transplant Proc. 1999;31:2168-2171.
28. Yasojima K, Kilgore KS, Washington RA, et al. Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res. 1998;82:1224-1230.
29. Keith JC Jr, Albert LM, Leathurby Y, et al. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R427-R438.
30. Writing G. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273:199-208.
31. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
32. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199-210.
33. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
34. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273-284.
35. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872-881.
36. Booth EA, Obeid NR, Lucchesi BR. Activation of estrogen receptor-alpha protects the in vivo rabbit heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2005;289:H2039-H2047.
37. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306:1954-1957.
38. Gabel SA, Walker VR, London RE, et al. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol. 2005;38:289-297.
39. Hulley SB, Grady D. The WHI estrogen-alone trial - do things look any better? JAMA. 2004;291:1769-1771.
40. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.